IL13 and colitis: Exogenous administration of IL-1β reduces the expression of colonic Th2 cytokines IL-4 and IL-13 and improves colitis, while exogenous IL-18 also reduces the severity of colitis but does not affect the expression of Th2 cytokines [151].